Impact of 68Ga-DOTAOTC PET for diagnosis of newly diagnosed or recurrent meningiomas

Medizinische Universität Innsbruck0 个研究点开始时间: 2013年12月17日最近更新: 2014年3月10日

适应症

试验速览

暂无简介。

•- The patient must be = 18 years and = 75 of age
•- MRI with suspicion of meningeal tumor and imperative necessity of resection
•MRI with confirmation of progressive disease of known and histological verified meningeal tumor (ICD-codes D32.0 and C70.0) and imperative necessity of resection
•- The patient must have an ECOG performance status 0-2
•- Signed and dated informed consent documented by the patient, indicating that the patient has been informed of all the pertinent aspects of the trial prior to study enrollment
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 25
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 10

•- Anamnestic known hypersensitivity or side effects of accomplished 68Ga-DOTATOC-PET prior to study enrollment
•- ECOG >2
•- The patient is active participant in another clinical trial, which investigates diagnostic and treatment of meningeal tumors
•- Other severe acute or chronic medical or psychiatric condition that would impart excess risk associated with study participation or which would make the patient inappropriate for entry into this study. The decision to enroll the patient in this study is in the judgment of the investigator
•- Pregnancy and Breastfeeding:
•Female patients who are pregnant or nursing
•- Evidence of incompliance of the patient to not comply with scheduled visits, treatment plans, laboratory test and other study procedures
•- Prior therapy with Octreotid or prior chemotherapy/local radiotherapy within the last 4 weeks

发起方